For research use only. Not for therapeutic Use.
Bepotastine besilate is a second generation antihistamine. Bepostatine besilate is used to treat allergic rhinitis and urticaria and pruritus. Bepotastine besilate inhibits the action of histamine by blocking histamine H1 receptors, antagonising the vasoconstrictor, and to a lesser extent, the vasodilator effects of histamine. Mast cell stabilisers inhibit degranulation and consequently the release of histamine by interrupting the normal chain of intracellular signals. The brand of Bepostatine besilate is Talion.
| Catalog Number | M106731 |
| CAS Number | 125602-71-3 |
| Molecular Formula | C21H25ClN2O3 |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Storage | Store at RT |
| IUPAC Name | 4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid |
| InChI | InChI=1S/C21H25ClN2O3/c22-17-8-6-16(7-9-17)21(19-4-1-2-12-23-19)27-18-10-14-24(15-11-18)13-3-5-20(25)26/h1-2,4,6-9,12,18,21H,3,5,10-11,13-15H2,(H,25,26)/t21-/m0/s1 |
| InChIKey | YWGDOWXRIALTES-NRFANRHFSA-N |
| SMILES | C1CN(CCC1OC(C2=CC=C(C=C2)Cl)C3=CC=CC=N3)CCCC(=O)O |
| Reference | </br>1:Bepotastine-induced urticaria, cross-reactive with other antihistamines. Kang JW, Lee J.Asia Pac Allergy. 2016 Oct;6(4):253-256. Epub 2016 Oct 31. PMID: 27803886 Free PMC Article</br>2:Histamine antagonist Bepotastine suppresses nasal symptoms caused by Japanese cedar and cypress pollen exposure. Kanzaki S, Hashiguchi K, Wakabayashi KI, Suematsu K, Okubo K.J Drug Assess. 2016 Sep 27;5(1):15-23. eCollection 2016. PMID: 27785375 Free PMC Article</br>3:Double-blind placebo-controlled study of bepotastine besilate in pediatric patients with perennial allergic rhinitis. Okubo K, Ichimura M, Koyama T, Susuta Y, Izaki H.Expert Opin Pharmacother. 2015;16(16):2395-408. doi: 10.1517/14656566.2015.1085511. Epub 2015 Sep 12. PMID: 26364765 </br>4:Comparative efficacy and bioequivalence of novel h1-antihistamine bepotastine salts (nicotinate and salicylate). Lim DS, Youn YS, Kwack SJ, Kwak HM, Lim SK, Kim JY, Um YM, Lee JD, Hyeon JH, Kim YJ, Kim HS, Lee BM.J Toxicol Environ Health A. 2014;77(22-24):1451-66. doi: 10.1080/15287394.2014.955833. PMID: 25343294 </br>5:Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%. Bergmann MT, Williams JI, Gomes PJ.Clin Ophthalmol. 2014 Aug 13;8:1495-505. doi: 10.2147/OPTH.S66637. eCollection 2014. PMID: 25152611 Free PMC Article</br>6:Comparative fasting bioavailability of 2 bepotastine formulations in healthy male Chinese volunteers: an open-label, randomized, single-dose, 2-way crossover study. Shentu J, Zhou H, Hu X, Wu G, Wu L, Zhu M, Zhai Y, Zheng Y, Liu J.Clin Ther. 2014 Apr 1;36(4):579-85. doi: 10.1016/j.clinthera.2014.02.020. Epub 2014 Mar 18. PMID: 24656153 </br>7:Bepotastine besilate for the treatment of pruritus. Bielory L, Duttachoudhury S, McMunn A.Expert Opin Pharmacother. 2013 Dec;14(18):2553-69. doi: 10.1517/14656566.2013.849242. Epub 2013 Nov 5. Review. PMID: 24191914 </br>8:Pharmacokinetic comparisons of bepotastine besilate and bepotastine salicylate in healthy subjects. Kim KA, Park JY.Clin Drug Investig. 2013 Dec;33(12):913-9. doi: 10.1007/s40261-013-0140-7. PMID: 24105252 </br>9:UPLC-MS/MS method for determination of bepotastine in human plasma. Choi YK, Chung YH, Nam YS, Kang DY, Kim H, Lee SE, Kim HR, Lee YS, Jeong JH.J Chromatogr Sci. 2014 Sep;52(8):886-93. doi: 10.1093/chromsci/bmt135. Epub 2013 Sep 10. PMID: 24023058 </br>10:Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial. Carr WW, Nayak AS, Ratner PH, Gow JA, McNamara TR, Williams JI; Bepotastine Besilate Ophthalmic Solution 1.5% (Bepreve) Study Group..Allergy Asthma Proc. 2013 May-Jun;34(3):247-54. PMID: 23484763 |
